Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Kwon, Jung Hee ^a   Lee, Namgyu ^b   Park, Jin Young ^a   Yu, Yun Suk ^a   Kim, Jin Pyo ^a   Shin, Ji Hye ^b   Kim, Dong Sik ^c   Joh, Jae Won ^d   Kim, Dae Shick ^d   Choi, Kwan Yong ^b   Kang, Koo Jeong ^e   Kim, Gundo ^f   Moon, Young Ho ^a   Wang, Hee Jung ^g  

^a CbsBioscience Inc   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Keimyung University School of Medicine   (South Korea)

^f Pukyong National University   (South Korea)

^g Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER STAGING; CELL VIABILITY; CLUSTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; EGFR GENE; FEMALE; FGFR1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MTOR GENE; PATIENT SATISFACTION; PDGFRBETA GENE; PREDICTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; UPREGULATION; VEGFR2 GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84879033996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064260     Document Type: Article

References (40)

1. Yang JD, Roberts LR, (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458.
2. Villanueva A, Llovet JM, (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410-1426.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
5. Zhu AX, (2012) Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 39: 493-502.
6. Huynh H, (2010) Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 80: 550-560.
7. Villanueva A, Llovet JM, (2012) Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 18: 1824-1826.
8. Ziegler A, Koch A, Krockenberger K, Grosshennig A, (2012) Personalized medicine using DNA biomarkers: a review. Hum Genet 131: 1627-1638.
9. Williams PM, Lively TG, Jessup JM, Conley BA, (2012) Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 18: 1531-1539.
10. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, et al. (2012) Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 18: 1515-1523.
11. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
13. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, et al. (2012) A novel classification of lung cancer into molecular subtypes. PLoS One 7: e31906.
14. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, et al. (2011) A melanoma molecular disease model. PLoS One 6: e18257.
15. Forner A, Reig ME, de Lope CR, Bruix J, (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30: 61-74.
16. Edmondson HA, Steiner PE, (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503.
17. Kwon JH, Kim J, Park JY, Hong SM, Park CW, et al. (2010) Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res 16: 5511-5521.
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
19. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM, (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317-328.
20. Buckley AF, Burgart LJ, Sahai V, Kakar S, (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129: 245-251.
21. Patel SH, Kneuertz PJ, Delgado M, Kooby DA, Staley CA 3rd, et al (2011) Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol 18: 3384-3390.
22. Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, et al. (2011) Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers 26: 108-116.
23. Zhou L, Huang Y, Li J, Wang Z, (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27: 255-261.
24. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676.
25. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, et al. (2012) Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55: 1443-1452.
26. Jia JB, Zhuang PY, Sun HC, Zhang JB, Zhang W, et al. (2009) Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 135: 847-854.
27. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, et al. (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18: 2290-2300.
28. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004.
29. Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, et al. (2009) Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 8: 2546-2558.
30. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, et al. (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16: 3548-3561.
31. Su MC, Lien HC, Jeng YM, (2005) Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 224: 117-121.
32. Nault JC, Zucman-Rossi J, (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31: 173-187.
33. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, et al. (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712.
34. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, et al. (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57: 108-115.
35. Ezzoukhry Z, Louandre C, Trecherel E, Godin C, Chauffert B, et al. (2012) EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131: 2961-2969.
36. Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, et al. (2012) Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol 57: 592-599.
37. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, et al. (2010) PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30: 4951-4958.
38. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, et al. (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13: 2673-2683.
39. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, et al. (2009) Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51: 725-733.
40. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, et al. (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14: 5124-5130.